Introduction
Article 23 of European Union (Eu) Directive 86/609/EEC required that Mem ber States promote the development and validation of alternative technologies and stated that the European Commission ( E c) "shall report before the end of 1987 on the possibility of modifying tests and guidelines" (European Parliament, 1986, Article 23 ) . This Directive was replaced by Directive 2010 / 63/E U on the pro tection of animals used for scientific purposes, which now requires that Member States develop and validate alternative approaches much more precisely and specifies that the ultimate objective is the "full replacement of procedures on live animals for scientific and educational purposes, as soon as it is scientifically pos sible to do so" (European Parliament, 2010, Recital 10 ). However, having followed theinitiativesofMemberStatesformorethan 3oyears, we see that developments to replace animal experiments occur more by accident than by design. Direc tive 2010/63/EU has not changed this either. This chapter explores the reasons why the development and approval of animal-free methods are not advancing more quickly, and why the numbers of animals used is not declining despite the development of new methods. Undoubtedly, there are complex, multifactorial reasons behind this. Our analysis leads us to the heart of the matter. There is no master plan and there are no responsible project managers who effectively pur sue the objectives of Directive 2010/63/EU at a national or EU level.
In 2015, we started collating individual measures in order to tackle the prob lems we encounter in our day-to-day work as an animal rights organization, defining five categories ( or pillars). We were encouraged to pursue our ideas by developments in the United States through concepts, such as Toxicolo gy in the 21st Century-A Vision and a Strategy ( Tox21) (Krewski et al., 2010 ) , as well as by the EU ban on the marketing of cosmetics tested on animals, which came into force in 2013. During this time, the Netherlands National Committee for the protection of animals used for scientific purposes (NCad) presented its plan, Transition to Non-Animal Research, referred to here as the NCad re p ort (NCad, 2016a) , becoming the first EU member state to present a road map for phasing out animal procedures and stimulating innovation without laboratory animals. Unfortunately, no EU Member State, so far, has publicly spoken out in favor of the Dutch initiative. On the contrary, its timeline has been criticized as being unrealistic, risking the safety of medical treatment, and hampering basic research. Only the government of the Brussels-Capital Region has put forward a plan to phase out animal experiments along the lines of the NCad report. Member States should show more support for such initiatives, which aspire to achieve the goal of full replacement stated in Directive 2010/63/EU. At the EU level, unfortunately, there is neither an overall strategy for phasing out the use of animals for scientific purposes nor for monitoring the implementation of the paradigm shift. It is important that changes take place, but how they take place is subject to debate.
Writing from the point of view of a German animal rights organization, the main focus of this chapter is Germany. Although Germany claims to be espe cially committed to developing animal-free methods, it ranks among the high est in terms of animal experiments in the EU, together with France and the United Kingdom. A master plan to end animal experiments requires suitable resources for effec tively reducing animal experiments and increasing market-ready animal-free methods. In the following we discuss steps towards that final goal.
On 1 December 2016, the Netherlands became the first EU Member State to present a road map for "phasing out animal procedures and the promo tion of innovation without laboratory animals" (NCad, 2016a, p. 3) . They are convinced that some uses of animals-currently required by law for safety testing of chemicals, food additives, pesticides, and (veterinary) medicines as well as the commercial launch of biological products ( e.g., vaccines )-can be phased out by 2025, while maintaining existing safety levels. However, their road map recommends that regulatory pre-clinical tests for the registration of new biological substances/products not be phased out by 2025 because there is a lack of replacement methods. Similarly, animal experiments in the field of "curiosity-driven" (NCad, 2016a, p. 38 ) basic research is not to be terminated by 2025 because there is a basic right to freedom of research; and, as no one knows the subject of research in advance, animal experi ments cannot be easily replaced with new animal-free methods. Therefore, it has been necessary to implement 10-year plans for each individual area of research. In the case of animal experiments in applied and translationalthe need for a broader definition of validation for the integration of new platform technologies into preclinical safety evaluation. The new in vitro systems, such as the chip technologies ( cell and tissue platforms, microelec trode systems with connected measuring devices), biomarkers, and the qual ity of cell and tissue types derived from human stem cells were also seen as needing evaluation in terms of safety for preclinical applications and ef ficacy. The pharmaceutical industry, which is the primary customer of the new multi-organ on a chip systems, should also be more involved (AIMBE, 2013) .
The EU Member States need to support the concept of To.x21, developed in the us (Krewski et al., 2010 ) . The concept's goal is to provide a new basis for risk and safety assessments of substances and products ( i.e., regulatory toxicology), using new techniques that are human-specific; and to promote the use of ani mal tests only in exceptional cases ( see also the Integrated Approaches to Test ing and Assessment adopted by the Organization for Economic Cooperation and Development, OECD, 2017). The OE CD now includes 35 countries around the world, across North and South America, Europe, and Asia.
A research focus is also needed on the implementation of cell culture media ready for practical application and for which no animals suffer, i.e., without the use of fetal bovine serum ( see Redmond, 2018, in this Volume) . Researchers in the us have been able to work with serum-free media in a defined system since 1995 (Schaffner et al., 1995) .
1.2
Pillar 2: Animal-free Methods in Teaching and Scientifi-c Research Have to Be Expanded The goal of Pillar 2 is to establish academic chairs-with corresponding per sonnel and financial resources for research and teaching and regular profes sorships-for animal-free research methods, courses of study in the life sci ences that do not use animals, a broad range of papers not based on the use of animals, and an increased number of theses and higher qualifications, with a focus on animal-free methods.
In Germany, for example, individual chairs in some federal states or Bundes liinder (Baden-Wiirttemberg, Berlin, Hesse, and North Rhine-Westphalia) have been established to develop methods to replace animal use. Researchers are thus able to offer students a perspective to get closer to the topic and to pre pare their theses with non-animal methods. However, there are still only a few chairs in some federal states. There is need for courses of study that address scientific questions using new animal-free methods. So far, students in life sciences courses, such as biology or human medicine, must, with few excep tions, participate in courses that use animals. Furthermore, where platforms Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access for alternatives to animal tests have been set up, the scientists involved usu ally investigate 3Rs methods (replacement, reduction, and refinement), which means that the scarce resources are spread across all three areas. Instead, the platforms' financial resources need to be exclusively available for replacement methods.
The situation is similar in other European Countries. There are a few na tional centers for alternatives to animal use, such as, the Finnish Centre for Alternative Methods, which teaches only animal-free replacement methods. In the private sector, Altertox Academy (formerly the Center for Alternatives to Animal Testing Academy) offers training for young scientists in replace ment methods. Others national centers, such as the Danish 3Rs-Center, the Swedish Toxicology Science Research Center, or the Romanian Center for Al ternative Test Methods, were founded to implement the mission of Directive 2010/63/EU and teach not only the replacement of animal use but also reduc tion and refinement. The range of programs of study for animal-free methods ( full replacement) should be expanded. It should be possible to choose courses of studies at European universities that will enable students to do research and develop methods without using animals.
1.3
Pillar 3: Bans on Animal Testing Must Be Consolidated and Expanded Since its review in November 2017, Article 58 of Directive 2010/63/EU has bare ly led to sufficient improvements for laboratory animals. In the next review, the EC must take into account any progress made in the field of alternative meth ods that may lead to an end to the use of animals, in particular non-human primates. The first step should be to repeal Article 55 of Directive 2010/63/EU, which allows Member States to provide exceptions from the regulations pro tecting non-human primates (European Parliament, 2010 ) ; it also allows ex ceptions from Article 2 1 which stipulates that procedures not be performed on animals if they involve severe pain, suffering, or distress. Therefore, with the approval of the EC, Member States may, for example, use monkeys in experi ments that involve severe pain, suffering, or distress.
Further bans should be introduced, including: a ban on patenting geneti cally altered animals; and a full ban on animal tests for household products and their components, including banning the sale of such goods ( analogous to the existing provisions for cosmetic products) is essential.
Viable European and national competency centers should be established, with the following tasks: creating transparency for the public, monitoring ad herence to EU animal welfare law, and setting up information offices for all stakeholders.
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Closer cooperation/collaboration with scientists and agencies in the us, which is more advanced in technological development. The us regulatory authorities are also not hesitant to search for and accept new animal-free methods. Even pharmaceutical and chemical companies think that the EC should be more orientated towards American models, such as the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) (Ettel, 2018) . Another example is the new Interagency Coordinating Commit tee on the Validation of Alternative Methods plan (National Toxicology Pro gram, 2018).
1.3.1
Suggestions for Implementing Existing EU Law The EC Department, Directorate-General for Environment, should have a Eu ropean competency center, for monitoring adherence to EU law and provid ing up-to-date information on pain, suffering/distress, and fear as well as on animal-free testing methods and other information relevant to this range of topics.
These additional tasks could also be integrated into existing structures, such as EURL ECVAM's EU Network of Laboratories for the Validation of Alterna tive Methods (EU-NETVAL), under the umbrella of the EC Directorate-General for Environment. So far, EU-NETVAL comprises laboratories in individual EU Member States that conduct validation studies and assess the reliability and relevance of new animal-free methods (EU-NETVAL, 2018). The European vali dation authority, EURL ECVAM, could also focus on transparency for the pub lic, provide information offices for all stakeholders, and monitor adherence to EU animal welfare law. It is also vital that a negative list be introduced that will stand up in court, defining tests that may no longer be conducted for ethical reasons.
The establishment of national competency centers as central institutions for informing and educating all stakeholders involved is also necessary. At a national level, these tasks could be completed by the EU National Committees in the Member States. The national information structures established thus far, in accordance with Article 49 of Directive 2010/63/EU, have laid the founda tion for such tasks.
The competency centers would be responsible for developing lists of criteria for assessing whether applications for animal experiments fulfill legal require ments, criteria that are lacking, thus far, but are necessary. This requires prac ticable assessment criteria for qualifying/quantifying the necessity, benefits, and ethical justifiability of the animal procedure as well as specifying the level of distress. The competency centers should also offer education schemes for all The approving authorities and monitoring agencies in the Member States should be provided with adequate finances, expertise, and staff.
Steps must be taken to ensure that the Member States implement the re quirements set out in Directive 2010/63/EU, without exception. In Germany, for example, although stipulated by Directive 2010/63/EU, the approving authori ties currently do not have a comprehensive right for evaluation when assessing applications for animal procedures, due to a decision made by the Higher Ad ministrative Court Bremen (Oberverwaltungsgericht Bremen, 2012) . Directive 2010/63/EU stipulates that project evaluation should consist of six evaluation points (European Parliament, 2010, Article 38, Section 2, Subsections a-f). It should include an evaluation of the project objectives, the predicted scientific benefits or educational value, and the severity of the procedures, and a harm benefit analysis of whether the suffering, pain, and distress inflicted on the ani mals is justified by the expected outcome, in light of ethical considerations and the ultimate benefit to human beings, animals, or the environment.
1-4
Pillar 4: Success Monitoring of the Increase of Animal-free Methods and the Reduction of Animal Experiments Is of Particular Importance This pillar is especially important. It stands for the need for quality manage ment, as it entails control measures that systematically document the progress of the paradigm shift. Unlike the other pillars, there are no approaches, as yet, to achieve this goal; they have to be established from the start. Definitive pa rameters should be determined for quantifying and qualifying the reduction of animal experiments and the increase in animal-free methods. A retrospective assessment for all animal tests conducted and the publication of their data crucial. Directive 2010/63/EU expressly provides for such a retrospective as sessment (European Parliament, 2010, Article 39 Moving from the development of an animal-free method to its implemen tation in the regulatory framework, which would lead to a broader range of applications, has taken too long. Periods of 12 to 15 years, or even longer, have been a matter of course (Hartung, 2015) . There is a lack of financial support for proof-of-concept studies as well as pre-validation and validation studies, so that developers spend a great deal of time seeking financial support. In addi tion, regulatory authorities become involved in this process at too late a stage (Hohensee and Bruning, 2016; Schoffl et al., 2000 ) .
According to NC ad and other researchers, there is a "growing focus on Syn thesis of Evidence", the experimental design and critical reviewing of exist ing animal models (Cronin, 2017, p. 39; NC ad, 2016a; Varga et al., 2010 ) . Just as the new animal-free methods must be validated, it is also necessary for animal testing to undergo systematic review.
Greater demand for national and international coordination of the promo tion and acceleration of validation, regulatory acceptance, and implementation of animal-free methods (NCad, 2016a). Directive 63/2010/EU provides for a long-term withdrawal from all animal experiments. Nevertheless, for many researchers, the development of replacement methods has not been the priority it should be. It still has a niche existence. Although some research groups focus on replacement, research and budgets at both the national and European levels are too low and should be embedded in a higher-level context. Here, more efforts are necessary.
2.1
Setting up Committees in Accordance with Directive 2010/63/E U With Directive 2010/63/EU, the EU and its Member States have set the long term goal of ending animal experimentation and promoting the development of replacement methods for animal experiments. The Directive must be enact ed in national law by all Member States. The amended German Animal Welfare Act (Tierschutzgesetz) took effect in July 2013, and the new Animal Welfare Lab oratory Animal Regulation (Tierschutz-Versuchstierverordnung) took effect in August 2013. However, while opportunities for achieving a higher level of ani mal protection should have been put in place, they were forfeited. Although the necessary legal basis exists in primary law, a maximum limit for pain or suf fering in animal experiments, and a ban on increasing animal experiments, by Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access eliminating the exemption clauses, were not enforced in German law (Peters and Stucki, 2012 ) . Furthermore, the comprehensive right of project evaluation pursuant to Article 36 of Directive 2010/63/EU was not implemented and was, instead, replaced by a qualified plausibility check (Hildermann, 2015) . Article 49 of Directive 2010/63/EU states that all EU Member States must establish National Committees for the protection of animals used for scien tific purposes (European Parliament, 2010 ) . In Germany, this role is performed by the Federal Institute of Risk Assessment (Bffi), which has established the German Centre for the Protection of Laboratory Animals (Bf3R), located at the Bffi, as set out in the amendment of the German Animal Welfare Act that took effect on July 13, 2013 (Bffi, 2017b . According to Paragraph 45 of the Ger man Animal Welfare Laboratory Animal Regulation, the National Committee advises the competent authorities and animal welfare committees on matters regarding the acquisition, breeding, accommodation, or care of vertebrates and cephalopods ( as defined in Paragraph 1 1 Section 1 of the Regulation); or the use of vertebrates and cephalopods in animal experiments. The National Com mittee also advises the competent authorities, in accordance with Paragraph 46 of the Regulation, on matters regarding alternatives to animal experiments (Bundesministerium fur Justiz und Verbraucherschutz, 2017).
The German Centre for the Protection of Laboratory Animals (Bf3R) was founded in the context of the animal welfare initiative ("Tierwohlinitiative") of the German Federal Ministry of Food and Agriculture (BMEL ) in 2015. While before the establishment of the Bf3R, the Centre for Documentation and Evaluation of Alternatives to Animal Experiments (zEBET) was of central importance, it has now been integrated into the Bf3R as one of five areas of competence. The competence areas are research and development of meth ods to reduce pain and suffering of laboratory animals (refinement); the Na tional Committee; development of alternatives in the field of toxicology; and coordination of research funding. The last two areas of competence were formerly tasks of ZEBET. However, the tasks of all competence areas are pre dominantly performed by Experimental Toxicology and ZEBET (Bffi, 2017b ) . Therefore, alternative methods are investigated, developed, and validated in accordance with the 3R principles. Thereby, the focus has shifted from the de velopment of replacement methods for animal experiments towards the 3Rs. Today, refinement and reduction of animal use is treated of, at least, equivalent importance.
2.2
Has Funding Been Increased in Recent Ye ars? 2.2.1
Funding on a National Level (Germany) Although an increasing number of projects are funded on a national level, those who conduct research in replacement methods criticize that disproportionate funding for animal experiments and an exaggerated perception of their im portance has led to a decades-long neglect of the development of replacement methods and a reticence to promote them actively (Baumgartl-Simons, 2017; Leist, 2016) .
2.3
Programs fo r the Development of Animal-free Methods: The Funding Has to Be Shared with Refinement Methods In Germany, projects are funded mostly by the German Federal Ministry of Education and Research (Bundesministerium fi.ir Bildung und Forschung, BMBF). BMBF, Bf3R, and the set Foundation together provide approximately €5. 7 million per year in funding for research into the development of replace ment and complementary methods for animal experiments based on the 3R principles. A few German federal states have established funding programs of their own, including Baden-Wiirttemberg, which provides €400,000 per year; and Rhineland-Palatinate, €70 1 000 every two years (see Table 3 .1). Some in dividual projects, such as postgraduate programs, are funded by the German research association, DFG; however, this funding is not dedicated to the devel opment of animal-free methods and, therefore, is not listed here. Note: This table presents an overview, not an official empirical survey.
On a state level, in Germany, it seems that an expansion of research asso ciations and professorial chairs has slowly begun. Some federal states have established research associations or professorial chairs and are providing ini tial funding for a finite period. For example, Baden-Wiirttemberg funds the Do erenkamp-Zbinden Chair of in vitro Toxicology and Biomedicine/Alternatives to Animal Experimentation with €200,000 to €400,000 annually. However, most of this funding is combined with research for the 3Rs as a whole, so fund ing for replacement methods alone cannot be quantified. For example, Berlin may soon take over the Berlin-Brandenburg research platform (BB3R), with an integrated postgraduate program; and it plans to establish an institute for alternatives to animal experiments, with €8.6 million, at the Charite Univer sity School of Medicine Berlin (Der Regierende Biirgermeister-Senatskanzlei Berlin, 2017 ). The current BMBF funding has expired and negotiations for fund ing on a state level are currently in progress. In Frankfurt, a professorship for pharmaceutical technology has been established, with 3R methods as its main research focus. During the next five years, €200,000 will be made available to be shared with another chair for refinement methods. Lower Saxony finances the research initiative R2N-Replace and Reduce, with €4.5 million. North Rhine-Westphalia is funding the Centrum fi.ir Ersatzmethoden zum Tierver such ( CERST-NRW), a center for replacement methods for animal experimen tation, with €500,000 per year for a period of five years. Since 1981, the BMBF has funded 530 projects for the development of 3R meth ods (BMBF, 2016) . The annual budget totals €5 million (although applicants for funding from this BMBF research budget, and for research prizes awarded for the development of alternatives to animal experiments, include develop ers of refinement methods for animal experiments, i.e. animal experimenters). So far, more than €170 million in funding has been provided in this area (Ho hensee and Bruning, 2016) . However, a 2011 study published by the Fraunhofer Institute for Systems and Innovation Research showed that about 30 per cent of the projects funded between 1981 and 2000 focused on refinement (Hiising et al., 2011) . In addition, few institutions or projects receive sufficient funding. For example, the BfR simultaneously supports about ten working groups for up to three years, each with an average of €35,000 per year. By comparison, the development of the in vitro pyrogen test required €6 million from development to implementation. The working group needed €400,000 per year (Thomas Hartung, personal communication, August 2016) . Numerous applicants com pete for the low project funds. The funding amount of about €5.7 million from the BMBF, set foundation, and Federal Institute of Risk Assessment is far too small, with no budget available for pre-validation and validation studies. Since the developers of refinement methods can also apply for these funds, even less money is available. Funding for refinement methods should have its own bud get. The half-hearted funding is intended to give the impression that Germany actively supports the development of new animal-free methods. However, it is not an expression of the decision to phase out animal experiments, instead, it slows down the development.
4
Additional Programs There are a few complementary funding programs to the main program, Alternatives to Animal Experiments, such as e:Bio-Innovative Competition Systems Biology, which runs until 2020. Systems biology unites complex high throughput experiments with mathematical modeling of the obtained data, to develop models to predict complex biological processes on cellular, tis sue, and organ levels as well as in the entire organism (BMBF, 2011). One of the complementary programs, BioOkonomie 2030-GO-Bio, aims to further develop innovative research topics in the field of life sciences to the point of making these available for economic implementation, like innovative start-ups (Bundesministerium filr Wirtschaft und Energie, 2017). This is in teresting for organ on a chip technology developments intended for market launch.
2.4.1
Funding Transregional/On a European Level There are also a few programs financed by more than one EU Member State, such as InnoSysTox-Innovative Systems Toxicology for Alternative to Animal Testing, a €3 million project financed jointly by Germany and the Netherlands (ZonMw, 2017). The application deadline was December 2014. Another pro gram is the translational funding initiative, Multilateral Collaboration in Computational Neuroscience: Germany-US -Israel-France ( BMBF, 2015a ). The EU-wide budget is unknown. In Germany, €90 1 000 -€225,000 in fund ing was available for a three-year term. The application deadline for the first run was November 2016. However, as previously noted, across the EU there is currently only one program financed by the Eu's funding framework Horizon 2020 dealing with animal-free issues, EU-ToxRisk, which deals with feasibility studies for methods that most urgently need to be developed in toxicology. In EU-ToxRisk, 39 project participants must share a budget of €30 million.
The research guidelines that define what methods are most urgent are set out by the scientists themselves, and not by the EC. This was the case with proj ect cluster SEURAT-I (SEURAT-I, 2013), which received €25 million in funding from both the EU and the industrial association, Cosmetics Europe. Cosmetics Europe also contributes to the funding for EU-ToxRisk (amount unknown) ( Cosmetics Europe, 2017 ) . Especially urgent areas of research should be stipu lated, and the development of animal-free methods must have priority. At the EU level, scientists seem to agree on the methods in most urgent need of de velopment; but in Germany, there is no agency that decides which methods need to be developed and provided with preferential funding. Apparently, a particular bone of contention is whether it is better to fund all research in discriminately, in the spirit of scientific freedom or originality, or to demand specific research into solutions for important questions (Hohensee, 2015) . In the case of achieving the end goal of full replacement, as set out in Directive 2010/63/EU, the answer is clear: Research developments should not be funded indiscriminately, but rather clear priorities are necessary, with replacement of foremost importance.
2.4.2
Funding on an International Level The us was the first country to take decisive steps towards ending animal ex periments, with the concept Tox21 (National Center for Advancing Transla tional Sciences, NCATS, 2017a). Toxz1 is a collaboration among the NIH, FDA, EPA, and the National Toxicology Program at the National Institute of Environ mental Health Sciences, with the goal of achieving better assessment of the toxicity of substances by using faster and more efficient human-specific meth ods in high-throughput technologies. To this end, fit fo r-p u rp ose cell models have been developed; and a high-throughput apparatus has been set up, which scans the gene expressions in human cells for alterations after they have been exposed to the test substance. The EPA has established its own National Cen ter for Computational Toxicology, in which prediction models are developed based on the new results ( Committee on Toxicity Testing and Assessment of Environmental Agents, 2007; NCATS, 2017b ).
A number of organ on a chip start-ups, most of them from the us, have been established to produce lab-scale prototypes. Zhang and Radisic ( 2017) de scribed the most important 29 start-ups, dividing their work into groups: start ups developing barrier functions, start-ups developing tissue-interface on a chip, and start-ups developing parenchymal-tissue on a chip. The first scientist to envision the possibility and pioneer the practice of quantitatively-simulating molecular and cellular biological systems, with in vitro devices was Profes sor Michael L. Shuler of Cornell University, New Yo rk (Hurelcorp, 2018) . To gether with Professor James J. Hickman of the University of Central Florida, Shuler founded the start-up, HESPER0S, in 2014 (HESPEROS, 2017 . Hickman developed the first serum-free media for hippocampal neuron cultures in 1995 (Schaffner et al., 1995) and published the first readouts of electrical and mechanical functions of neurons in 1998 (Ravenscroft et al., 1998) . Together with Shuler and others, Hickman integrated cardiac, muscle, neuronal, and liv er modules in a microphysiological system, under continuous flow conditions in a serum-free defined medium, utilizing a pump-free platform (Oleaga et al., 2016) . So far, HESPER0S has successfully tested six organs on a chip (Miller, 2017) .
TissUse, a German spin-off from the Technical University of Berlin, was founded by Dr. Uwe Marx in 2010. The initial focus of this company was on the development of two-organ and four-organ models. Today, like HE SPERO S, their ultimate goal is to develop a human on a chip, integrating at least 10 or gan-like tissue constructs of human origin. Instead of using a gravity-driven flow, like Hesperos, the TissUse platform contains a built-in micropump, driv en by an external pneumatic controller. A second microfluidic circuit ensures drainage of the fluid excreted through a kidney's epithelial cell l aye r. The four organ chip with intestine, liver, skin, and kidney is already available and can be co-cultured for up to 28 days (M aschmeyer et al., 2015) . The Wyss Institute for Biologically Inspired Engineering at Harvard University in Boston has pro duced 19 university start-ups (Wyss Institute, 2018) and is known for its organ on a chip developments. One of the current research results is a pulmonary thrombosis model on a chip. The research was co-financed by the Defense Ad vanced Research Projects Agency (DARPA), Janssen Pharmaceuticals (Jain et al., 2018) , and funding from NCATS (NCATS, 2018).
The Center for Alternatives to Animal Testing ( CAAT) was founded in 1981 by Alan Goldberg, a professor at Johns Hopkins University in Baltimore. CAAT was then financed by the American Cosmetic Toiletry and Fragrance Association (CTFA), which was interested in the development of replacement methods for testing their products ( CAAT, n.d. a). CAAT's goal is to create fundamental knowledge regarding possible methods for replacing tests using whole organ isms (i.e. living animals) with alternative methods in the development and testing of commercial and therapeutic products. CAAT established its own in vitro toxicology laboratory in 1985. In 1988, the cosmetics company, Avon, financed the first program for replacing animal experiments in the field of con tact allergies. Since 1989, CAAT has also been supported by government agen cies and, as of 1992, by the EPA. CAAT-Europe, at the University of Konstanz in Expanding education and research towards science without animal experiments is crucial, as only a small group of researchers currently work on replacement methods. Despite the aforementioned funded individual profes sorial chairs, there is still no way of completing a course of studies that would equip students with the professional capacity to develop alternatives to ani mal experiments. In order to complete a thesis at one of the newly established chairs ( see above), the student must first have studied one of the more common courses of studies, such as biology, medicine, veterinary medicine, biochemis try, pharmaceutics, toxicology, or biophysics, which, for the most part, contin ue to use animals for training ( SATI s, 2017a ) . Only very few tertiary institutions allow the use of alternatives to animal dissection on ethical grounds. Instead, tolerance towards alternatives to the use of animals in training courses has decreased, depending on the course organizers' attitude. Only four German State Higher Education Acts (North Rhine-Westphalia, Hesse, Saarland, and Bremen) allow the right to decline using animals on ethical grounds (SATIS, 2017b ). Most students quickly get used to using animals because they do not want to belong to a fringe group, without prospects of gaining a professional foothold, or they want to keep their options open. The lack of opportunities for attaining qualifications in animal-free courses of studies leads to a lack of qualified young scientists in the area of animal-free methods, so that fund ing bodies sometimes argue that the reticence in providing finances results from insufficient scientific standards (Hohensee, 2015) . The lack of political will means that the subject continues to go in circles.
5
The Time-consuming Va lidation Process The time taken for the validation and approval of animal-free testing meth ods urgently needs to be shortened. The broadening of funding by the BMBF program, Alternatives to Animal Testing, to include strategies for imple menting newly developed methods as replacements for animal experiments (BMBF, 2015b, Module 11), is a first step in the right direction; but it is by no means enough. Validation studies, in particular, are extremely expensive and time-consuming and go through the bottleneck of the European validation authority, EURL ECVAM, which has limited capacities. There are simply not In Wh ich Areas Are There Insufficient Animal-free Te st Methods and Why ? In this section, we focus on the field of toxicology alone. Relevant animal-free methods in the field of toxicology could also be applied to other areas. There has been great progress in the development of replacement methods in the area of local toxicity testing ( e.g., skin and eye tests), where many animal ex periments have already been replaced (AltTox, 2016) . However, there are still no replacement methods for long-term studies of the organism as a whole, for example, in the area of inhalation toxicity or tests for reproductive damage and damage caused to offspring. The development of replacement methods for testing environmental toxicity is also only rudimentary.
The goal of the holistic approach is to be able to depict the entire organism in a simplified and miniaturized form. This is a complicated process because individual organs, their biology, and their interactions within the body are highly complex. In order to replace this complex organism in experiments, sci entists aim to create a human on a chip, in which all the vital human organs are combined on a chip of miniaturized scale of about 1:10,000. At present, about eight miniaturized organs can be simulated and interconnected (Ingber, 2017 ) . However, to construct a human surrogate for drug screening, scientists are convinced that it will not be necessa ry to replicate a perfect human body but simply to provide a better predictive model than animal models (Wang et al., 2016) . For such simplified models, many different technical approaches have been developed; for example, according to chip fabrication techniques, medium composition, delive ry systems of media, nutrients, oxygen, metabo lites, and so forth, have a strong influence on the quality of cell or organ cul tures and the results. Wang et al. (2016) provide an explorato ry overview of current developments in multi-organ systems and their pro and cons. Since each start-up presently holds only a piece of the entire puzzle, the authors recommend that the multiple companies should be motivated to join forces to combine their techniques and patents, thereby fostering the continued evolu tion of more advanced products. In many cases, the viability of organoid sys tem cultures cannot, currently, be guaranteed for long-term investigations.
Depending on the laboratory, there are groups whose cell systems can be utilized for just one week and others for three months (Epit helix, 2017 ). These differences may result from the organs' different needs and the difficulties of recreating miniaturized human organs, especially in the case of such vital organs as the liver or kidneys. Wang et al. (2016) discuss the need for a common culture medium, with full chemical definition, as a blood sur rogate that can maintain the viability and function of various organ models and by the use of extracellular matrices can influence the reproducibility and physiologically-realistic ratio of liquid to cell volumes in the (multi-) organ on a chip system.
Methods in the field of inhalation toxicology are advanced with superficial and deeper respirato ry epithelium in vitro and with, in some cases, a viability or usability of more than a month (Epithelix, 2017) . Lung models have been in use for quite some time (Esch, Bahinski and Huh, 201s; Huh et al., 2010 ) . One method, having achieved general approval, is currently undergoing a validation study in Germany (Hoffmann et al., 2017) . However, it was initially intended for replacing animal experiments in the area of acute toxicity. Devel opments in the area of long-term toxicity are not as advanced and are being explored in a feasibility study within the framework of the EU project cluster, EU-ToxRisk (EU-ToxRisk, 2016).
Recreating a reproductive tract in a multifluidic system is a particular chal lenge. Some advancements have already been made, such as the develop ment of 3D cell culture models of animal Fallopian tubes, in which emb ry os can even develop in the "tubular fluid" ( Chen et al., 2017 ) . There are models of the vagina and in vitro test systems with ectocervical cells and fibroblasts, which have been developed to test substances for their irritant, toxic, or endo crine disruptive effects (Ayehunie et al., 2016; Land ry et al., 2016 reproductive cycle has also been created, using murine ovarian follicles in vi tro, to investigate the mechanisms of reduced fertility (Zhu et al., 2016) . First steps have been taken to culture parts of female ovaries, using human follicles, to study the maturation processes (Laronda et al., 2014) . There are also initial developments for studying the hormonal cycle, using human ovarian tissue as well as mice and human follicles (Skory et al., 2015) . More advanced is a system (EVATAR) to simulate the 28-day hormone profile of the female reproductive tract to study its influence on reproductive tissue (Xiao et al. 2017 ). However, due to species differences between mice and humans, the use of murine tissue can only be a first step. The goal is to construct models with human-specific tissue material (for an overview see Eddie et al., 2015) . A repro-on a chip could be used in the future to recreate mechanistic developments and disorders in the development of the reproductive organs in the field of basic and applied research but not reproductive behavioral disorders or detrimental effects on offspring. Other solutions would have to be found for these. The project cluster EU-ToxRisk is also conducting feasibility studies in the field of developmen tal and reproductive toxicology (EU-ToxRisk, 2016). Unfortunately, hormonal regulation ( feedback loops with h yp othalamus, adenoh yp ophysis, and th yr oid, which affect the tissues) and immune defense, which would allow the modula tion of a miniature human on a chip, are lacking.
What is appealing about this human on a chip technology is that automa tion could rapidly shorten the time and cost of development by using large rooms filled with robotic systems to simultaneously run tests on a multitude of chips, with different concentrations of a variety of substances, without the disruption of human factors ( e.g., introduction of bacteria, measuring errors, or pipetting errors). This would facilitate more targeted, cheaper, and faster development and production and make it more attractive for industry.
Why Aren't Developments Progressing More Quickly in Germa ny ?
The development of animal-free methods primarily depends on the advance ment of knowledge (Linz School of Education, 1999; Schmiel, 2006) as well as other factors, such as efficient methods of investigation and measurement, high-performance research facilities with a workplace environment conducive to creativity, innovative staff, and, most significantly, sufficient funds. The fol lowing observations regarding these factors are restricted to Germany.
3.2.1
Powerful Methods of Investigation and Measurement Modern molecular biological and biochemical methods, insights into cell cul ture, stem cell research, chip technology, omics technologies, computers of high performance, algorithms, potent imaging techniques, and bioprinters have considerably advanced the development of animal-free testing methods ( BM BF, 2016; DFG, 2017 ) . While these powerful methods should also be available to universities and other research facilities, they would involve considerable cost. Several facilities are currently known to need money for 3D bioprinters in order to advance research on non-animal replacements, including the Institute of Veterinary Anatomy of the Free University Berlin. It is possible that some research remains at a certain level of development due to lack of instruments. This situation has been recognized by the German Research Foundation (DFG, 2017 ) . The problem could be addressed by establishing decentralized method centers, whose services would be available to all authorized research institutes. Collaborations with extramural institutes ( e.g., Fraunhofer Institutes) also need to be facilitated and, perhaps, expanded.
3.2.2
High-performance Research Facilities with a Workplace Environment Conducive to Creativity In addition to up-to-date research topics, the workplace environment is also important for the research staff, for example, in terms of hierarchy, recogni tion, and interdisciplinary collaboration. Recent years have seen progress in this regard. New university courses have also been introduced, some of which are suitable for the development of replacement methods for animal experiments, such as Medical Biotechnology (Technische Universitat Berlin, TU-Berlin, 2017), Biomedical Computing (xStudy SE, 2017a), Life Science En gineering (Hochschule fur Technik und Wirtschaft Berlin, HTW-Berlin, 2017), Biomedical Engineering (xStudy SE, 2017b ), and Biochemistry and Molecular Biology (Universitat Bayreuth, 2018). There are increasingly more student ex changes between international partner universities (xStudy SE, 2017a).
3.2.3
Innovative Staff Understandably, aspiring students and postgraduates, among others, are in fluenced by their career prospects when choosing suitable fields of study. This choice involves assessing how much return they can actually get on their in vestment in their course of studies. The best employees go to institutes with the best reputations ("everyone wants to go to Harvard"); institutes that do the best research, who are best known, that have significant influence in the sci entific community, that are not economically threatened, and that pay their staff well. For this reason, attractive degree courses in the area of animal-free methods are needed ( e.g., Medical Biotechnology at TU-Berlin). There should also be a climate of internationality, enabling an exchange of know-how and strategic thinking in problem solving. At present, there are professorial chairs in Germany, where one can learn animal-free research and testing methods; 2017) . Tax relief for companies that invest in research has been de manded for many years and should be implemented (Ver band der Chemischen Industrie, 2017). In the us, there are more ambitious programs leading to bet ter and more innovative scientific outputs. NCATS at NIH and DAR PA recently funded a us$150 million program for grants in the field of toxicity testing, drug efficacy evaluation, and disease modeling (Wang et al., 2016) . It seems that there is a strong motivation to make the new systems successfully applicable. In Europe, there are no such programs available. Funding programs are frag mented into small individual measures with much smaller budgets. So far, only the Netherlands has clearly expressed its intentions. Other Member States are reserved, expressing themselves at best behind closed doors and referring to their cooperation within the framework of their National Committees. Many researchers who use animal methods likely have little interest in the success of the Dutch plan. Such reservation by Member States could be a barrier towards the success of the plan. 
.2
The Development of the NCad Report The NCad plan is not the result of a whim but rather the product of years of expert preparation, in which all stakeholders were involved. In June 2014, the Dutch Ministry of Economic Affairs commissioned the expert group, The Think Tank on Supplementary Financing for Alternatives to Animal Testing (De Denktank Aanfullende financierung alternatieven voor dierproeven), to develop recommendations for additional funding for the development of "in novations without laboratory animals" (NCad, 2016a, p. 42,) . The Think Tank presented its 140-page report, In Transition! The Netherlands leads the way in laboratory animal-free innovations, in October 2015 (Henneman et al., 2015) . Based on this report, on April 8, 2016 1 the Minister of Agriculture, Martijn van Dam, assigned NC ad the task of presenting a strategy for phasing out animal procedures. Van Dam specified that the strategy should involve the National Institute of Public Health and Environmental Protection (Rijksinstituut voor Volksgezondheid en Milieu Netherlands, RIVM ). RIVM has significant exper tise in toxicity testing and is both national and international coordinator for 3Rs methods. van Dam instructed NCad to name specific phasing-out targets and stated that the legally required toxicity tests should be phased out within 10 years, which would reduce the number of animals used in experiments by 10% in the Netherlands. He also emphasized the goal, formulated in the Think Tank's recommendations, that the Netherlands become the world leader in laboratory animal-free innovations by 2025 (NCad, 2016b .
NCad conducted two expert workshops on June g and July 7 1 2016 in co operation with the RIVM (NCad, 2016a, p. 13 (Koeter, 2016) . As of November 17, 2016, the group had 245 members, but unfortunately it delivered little of substance (NCad, 2016a, p. 51) . A public consultation was held on September 8, 2016 in Den Haag, where a broad range of organizations commented on specific recommendations, such as "It is possible to move away from the regulatory animal procedures within the next ten years" (NC ad, 2016a, p. 51 Regulatory tests: -"The use of laboratory safety testing for chemicals, food additives, pes ticides, and (veterinary) medicines can be phased out by 2025 whilst maintaining the existing safety level" (NCad, 2016a, pp. 3, 17) . -"The use of laboratory animals in regulatory tests for the release of biological products, such as vaccines, will be phased out by 2025 whilst maintaining the existing safety level" (NCad, 2016a, pp. 17-18 ). -Regulatory preclinical tests associated with the registration of new biological substances/products cannot be phased out by 2025. "At this stage, however, due to the complex composition of these products and generally complex mechanism of action, the regulatory preclinical research associated with the registration of new biopharmaceuticals ( such as vaccines or monoclonal antibodies) cannot be phased out at the same pace" (NCad, 2016a, pp. 17-18). 2.
Basic scientific and medical research: -Animal experiments in the field of "curiosity-driven basic research cannot be phased out by 2025. Therefore, individual ten-year plans are necessary for each area of research" (NCad, 2016a, p. 15) . The complex procedures and interactions in an organism as a whole cannot be sim ulated at the current time. -"Within the field of fundamental scientific research, the reduction or phasing out of the use of animals is not realistic in the short term in all areas of research" (NCad, 2016a, p. 18) . 3.
Applied and translational research: -While animal experiments in applied and translational research (im plementation of preclinical research in clinical development) cannot be phased out by 2025, the development of replacement methods can be accelerated. This includes investing more in human-specific mod els and less in animal models. The Netherlands aims to become "an international leader" in this respect (NCad, 2016a, p. 19 ). 4.
Education and training: -"By focusing on animal-free practices and actively reflecting on the use of laboratory animals in education, the use of laboratory animals for ed ucation and training can be significantly reduced" (NC ad, 2016a, p. 19 ).
4-4
Transition Objectives, Transition Strategy and Management of the Tra nsition NCad has found that there is a realistic chance of completely phasing out animal experiments in the areas of regulatory safety tests ( for chemicals, food additives, pesticides, and veterinary and human medical products) and regulatory tests for the release of biological products ( e.g., vaccines) by 2025. This requires a transition strategy and management of the transition. The de velopment will not take place on its own. Therefore, we strongly recommend the development of NCad's transition objectives, transition strategy, and pro gram for transition management.
441
Transition Objectives The transition objectives refer to a paradigm shift away from existing mind sets and practices, which are combined with animal use, to a strong focus on innovations without laboratory animals. In regulatory research, this means a significant reduction in the use of laboratory animals; in the field of basic re search, the development of a ten-year vision for each area; and in the field of applied and translational research, more rapid progress, for example, through the development of human models for human diseases. Furthermore, the use of animals in education and training can be significantly reduced (NC ad, 2016a, pp. 3-4) .
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Transition Strategy NC ad has stated that the following is necessary for a good transition strategy: -the use of human data -international cooperation for a new approach to risk assessment -multidisciplinary cooperation on the development and approval of replacement methods -monitoring of the evaluation and dissemination of replacement methods -monitoring and evaluation of the reduction of animal procedures ( since the contribution replacement methods make towards the reduction of the number of animals used in the Netherlands cannot currently be proven) -development of an innovation index for replacement methods ( data warehouse, directory) in collaboration with other countries (NCad, 2016a, p. 24 
5

Ev aluation and Conclusions
An analysis of the 108 reports that led to the decisions presented in the NCad report, showed that the phase-out timeline is not an unrealistic idea. The phase-out timeline is based on the results of two years of intense consultation and work, involving representatives of stakeholders from the fields of science, applied research, contract research, laboratory animal science, medicine, replacement of animal testing, and animal welfare (NCad, 2016c, p. 2) . The phase-out timeline was developed with all participating groups; as such, the road map is certainly ambitious but by no means unrealistic. It is, therefore, disconcerting that other EU Member States have either ignored or rejected the Dutch plan, and none have expressed support.
The Way Forward
What has to be done to rigorously pursue the "phasing out of animal proce dures and the stimulation of innovation without laboratory animals" (NCad, 2016a, p. 3)? With the NCad report, Tra nsition to Non-A nimal Research, the Netherlands has not only presented an opinion but has developed a con cept for purposefully affecting a paradigm shift. The NCad report contains clear transition objectives, a transition strategy, and a program for transition management. Our association, People for Animal Rights Germany, proposes that the following can be achieved, based on the Dutch concept and includ ing our five pillars and our demand for a master plan for phasing out animal experiments:
The EU Member States' National Committees (European Parliament, 2010, Article 49) should endorse the N Cad plan. The national responsible ministers ( especially the ministers responsible for the animal welfare, science, and research portfolios) should advocate for the adoption of the NC ad concept, to encourage the governments of the Member States to implement the Dutch plan in their own countries. Parallel to this, we rec ommend that the responsible national ministers vote in their respective Councils of Ministers to support the NC ad plan at an EU level. Based on the national governmental resolutions and the resolutions of the EU Council of Ministers, the EC should adopt the NC ad concept as a principle for action for reducing animal testing and funding animal-free procedures. Political action is also urgently needed to stop the different stakeholders working against each other. These objectives can be achieved by the EU Members States' ministers responsible for the animal welfare, science, and research portfolios, by developing a new approach to assessing the risks posed by substances and asserting this internationally beyond the EU. The pivotal issue is the actual risk (risk assessment) and not the substances' overall hazard po tential (hazard assessment) (NCad, 2016a, p. 20) .
In the short term, the Netherlands intends to compile a priority list for areas of regulatory testing that lack animal-free methods. Other EU Member States should actively support the Netherlands in compiling this list. The EU Member States and the EC should then approve funding pro grams for these procedures. Funding programs should only be available for animal-free testing methods and provide continuous funding, from development to final validation. It is necessary that the responsible ministers in the EU Member States optimize the validation process. The results of methods to be validated must be compared with human data and not with data from animal ex periments (NCad, 2016a). The time needed for the validation process should also be shortened. The responsible ministers in the EU Member States should agree on the introduction of a monitoring system for quality assurance during the transition process, which would monitor the development and applica tion of animal-free procedures and the phasing out of animal procedures, allowing timely intervention in the case of negative developments. The Dutch Minister of Economic Affairs will set up sub-domains in order to draw up ten-year plans for the different areas of basic research. The plans will name realistic objectives for "innovations without laboratory animals" (NCad, 2016a, p. 3) . This task is a particular challenge, as basic research has, until now, been regarded as sacrosanct. This makes it all the more important that all EU Member States actively participate in the drawing up of these plans.
Final Remarks
We strongly recommend transforming the current plan, Tra nsition to Non Animal Research, proposed by NC ad, from an uncoordinated single process to a targeted joint project, in which all stakeholders stand behind the same goals and actively pursue them based on an overall plan. The NCad report de scribes crucial objectives: ending animal procedures for regulatory tests; listing and prioritizing the animal-free procedures that need to be developed; and drawing up ten-year plans for phasing out animal procedures in the different areas of basic research. Under the leadership of politics, the principles that underlie the NCad report should be implemented in the EU Member States, supported by the EC, and ideally in step with international regulatory authori ties and scientific bodies. The implementation should be ensured by national and international project management, accompanied by a monitoring system, and made transparent to the public. A joint pursuit of the Dutch concept by the other EU Member States would work towards achieving the goal of Recital 10 of Directive 2010/63/EU to replace animals for scientific and educational purposes. This requires a common will and joint preparation of individual plans in European ( or even international) workshops with all major stake holders, in particular science, industry, and public authorities. The successful phase out of animal testing in the field of cosmetics, which is gradually tak ing place worldwide, as well as current multi-organ on a chip developments across many countries, have shown that it is possible to achieve these goals together.
